Table 1.
Study Population Characteristics
| Parameter | NoVT/VF | VT/VF | P = |
|---|---|---|---|
| Gender | 39 males/11 females | 35 male/10 females | 0.983 |
| Age (years) | 64 ± 12 | 62 ± 10 | 0.493 |
| NYHA class | 1.55 ± 0.5 | 1.71 ± 0.4 | 0.255 |
| LVEF (%) | 37 ± 8 | 34 ± 10 | 0.078 |
| s/m vessel disease | 13/37 pts | 6/39 pts | 0.123 |
| Diabetes mellitus | 6 pts (12%) | 7 pts (15.6%) | 0.615 |
| PAC/recording | 107 ± 109 | 101 ± 142 | 0.595 |
| PVC/recording | 259 ± 186 | 386 ± 243 | 0.125 |
| BB/AAD (%) | 50/0 pts | 45/0 pts | |
| metoprolol‐22 | metoprolol‐24 | 0.363 | |
| bisoprolol‐15 | bisoprolol‐11 | 0.370 | |
| carvedilol‐13 | carvedilol‐10 | 0.530 | |
| ACE‐I | 41 pts (82%) | 43 pts (96%) | 0.398 |
| Statins | 29 pts (58%) | 22 pts (49%) | 0.374 |
| PVC couples | 24 pts (48%) | 28 pts (62%) | 0.453 |
| nsVT | 14 pts (28%) | 18 pts (40%) | 0.385 |
| HR avg (E) (bpm) | 66 ± 10 | 67 ± 5 | 0.535 |
| HR avg (N) (bpm) | 63 ± 9 | 63 ± 6 | 0.317 |
| HR avg (D) (bpm) | 70 ± 11 | 69 ± 5 | 0.986 |
ACE‐I = angiotensin converting enzyme inhibitor; BB/AAD = beta‐blockers/true antiarrhythmics; HR avg (D) = average heart rate from the daytime period; HR avg (E) = average heart rate from the entire recording; HR avg (N) = average heart rate from the nighttime period; LVEF = left ventricle ejection fraction; nsVT = nonsustained ventricular tachycardia; NYHA = New York Heart Association; PAC = premature atrial contraction; PVC = premature ventricular contraction; s/m‐ vessel disease = single or multivessel disease.